Dr. reddy's successfully completes phase 1 study of drl_tc, a proposed biosimilar of tocilizumab

Hyderabad, india--( business wire )--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy; hereafter referred to as “dr. reddy's”), a global pharmaceutical company, announced that its tocilizumab biosimilar candidate, drl_tc, successfully met its primary and secondary endpoints in a phase 1 study. this phase 1 study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety and immunogenicity of dr. reddy's tocilizumab biosimilar candidate in comparison to reference products.
RDY Ratings Summary
RDY Quant Ranking